Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I-env gene

Kazanji, Mirdad; Bomford, R.; Bessereau, Jean-Louis; Schulz, Thomas

doi:10.1002/(sici)1097-0215(19970410)71:2<300::aid-ijc27>3.0.co;2-j

Cited by 26 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, protection has been observed in the absence of an antibody response (10,20), suggesting that cell-mediated immunity plays a key role. We used the recombinant NYVAC vaccine containing a Gag component in the second immunization protocol for the following reasons.…”

Section: Discussionmentioning

confidence: 99%

“…HTLV-1-specific cytotoxic T lymphocytes were recovered from rats immunized with recombinant adenovirus 5 and boosted with naked DNA containing the HTLV-1 env gene (20). More recently, Robinson et al (31) compared eight immunization protocols in rhesus macaques and found that the most promising protocol for protection against HIV was priming with naked DNA and boosting with recombinant vaccinia virus.…”

Section: Discussionmentioning

confidence: 99%

“…WR-SFB5env induced antibodies against gp46 that were not neutralizing and conferred only partial protection (13). We evaluated WR-SFB5env in rats: animals primed and boosted with this recombinant vaccinia virus developed antibodies against the HTLV-1 Env protein and showed partial protection against challenge from HTLV-1-infected MT2 cells (20). Cynomolgus macaques immunized with WR-SFB5env were also protected against challenge (17).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity and Protective Efficacy of Recombinant Human T-Cell Leukemia/Lymphoma Virus Type 1 NYVAC and Naked DNA Vaccine Candidates in Squirrel Monkeys (Saimiri sciureus)

Kazanji

Tartaglia²,

Franchini

et al. 2001

J Virol

Self Cite

View full text Add to dashboard Cite

We assessed the immunogenicities and efficacies of two highly attenuated vaccinia virus-derived NYVAC vaccine candidates encoding the human T-cell leukemia/lymphoma virus type 1 (HTLV-1) env gene or both the env and gag genes in prime-boost pilot regimens in combination with naked DNA expressing the HTLV-1 envelope. Three inoculations of NYVAC HTLV-1 env at 0, 1, and 3 months followed by a single inoculation of DNA env at 9 months protected against intravenous challenge with HTLV-1-infected cells in one of three immunized squirrel monkeys. Furthermore, humoral and cell-mediated immune responses against HTLV-1 Env could be detected in this protected animal. However, priming the animal with a single dose of env DNA, followed by immunization with the NYVAC HTLV-1 gag and env vaccine at 6, 7, and 8 months, protected all three animals against challenge with HTLV-1-infected cells. With this protocol, antibodies against HTLV-1 Env and cell-mediated responses against Env and Gag could also be detected in the protected animals. Although the relative superiority of a DNA prime-NYVAC boost regimen over addition of the Gag component as an immunogen cannot be assessed directly, our findings nevertheless show that an HTLV-1 vaccine approach is feasible and deserves further study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity and Protective Efficacy of Recombinant Human T-Cell Leukemia/Lymphoma Virus Type 1 NYVAC and Naked DNA Vaccine Candidates in Squirrel Monkeys (Saimiri sciureus)

Kazanji

Tartaglia²,

Franchini

et al. 2001

J Virol

Self Cite

View full text Add to dashboard Cite

show abstract

“…A nude rat model of ATL-like symptoms has been used to assess cytotoxic T-cell responses against Tax-encoding DNA vaccination [75,76]. Rats immunized with recombinant adenovirus vector expressing Env have been demonstrated to elicit CTL and detectable humoral immune responses but without protective effects [77]. To evaluate CTL responses most relevant to human application, we have focused on developing CTL peptide immunogens in HLA-A*0201 transgenic mice, and have used a recombinant vaccinia virus challenge model to evaluate protective efficacy [78][79][80].…”

Section: Htlv-1 Vaccine Studies and Their Animal Modelsmentioning

confidence: 99%

Advances in HTLV-1 Peptide Vaccines and Therapeutics

Lynch

Kaumaya²

2006

CPPS

View full text Add to dashboard Cite

In the past two decades a large initiative has been put forth to understand the biological and pathogenic properties of the human T-cell lymphotropic virus type 1 (HTLV-1); this has ultimately led to the development of various experimental vaccination and therapeutic strategies to combat HTLV-1 infection. The focus of this work is to outline key targets for the design of therapeutics for HTLV-1, such as fusion mediated by the envelope glycoprotein, and to discuss reports of novel vaccines or therapeutics. These strategies include peptide, recombinant protein, DNA, and viral vectors. The final focus of this review is to acquaint the reader with vaccine approaches developed in our laboratory over the last decade. These strategies include the development of envelope glycoprotein derived B-cell epitopes for the induction of neutralizing antibodies, as well as a strategy to generate a multivalent cytotoxic T-lymphocyte (CTL) response against the HTLV-1 Tax antigen.

show abstract

“…The defect, which is probably situated at the level of Rex and protease activities, could be overcome by replacement of the env gene with the corresponding envelope sequence of an ecotropic Moloney murine leukemia virus (Delebecque et al, 2002). Transgenics and direct HTLV infection in rats yielded various pathologies (thymoma, chronic destructive arthritis) and made it possible to evaluate the immune response (cytotoxic activity, involvement of major histocompatibility complex class I downregulation), to assess therapeutic strategies (vaccination, adoptive transfer) and to test the routes of infection (Kazanji et al, 1997a;Ohashi et al, 2000Ohashi et al, , 2002Hanabuchi et al, 2001;Nakamaru et al, 2001;Kikuchi et al, 2002;Sugaya et al, 2002;Hasegawa et al, 2003). A major contribution of another species, the rabbit, was the identification of viral genetic determinants required for HTLV-1 infectivity and pathogenesis (Leno et al, 1995;Collins et al, 1998;Simpson et al, 1998;Bartoe et al, 2000).…”

Section: Introductionmentioning

confidence: 99%

Reduced cell turnover in lymphocytic monkeys infected by human T-lymphotropic virus type 1

et al. 2005

Self Cite

View full text Add to dashboard Cite

Understanding cell dynamics in animal models have implications for therapeutic strategies elaborated against leukemia in human. Quantification of the cell turnover in closely related primate systems is particularly important for rare and aggressive forms of human cancers, such as adult T-cell leukemia. For this purpose, we have measured the death and proliferation rates of the CD4 þ T lymphocyte population in squirrel monkeys (Saimiri sciureus) infected by human T-lymphotropic virus type 1 (HTLV-1). The kinetics of in vivo bromodeoxyuridine labeling revealed no modulation of the cell turnover in HTLV-1-infected monkeys with normal CD4 cell counts. In contrast, a substantial decrease in the proliferation rate of the CD4 þ T population was observed in lymphocytic monkeys (e.g. characterized by excessive proportions of CD4 þ T lymphocytes and by the presence of abnormal flower-like cells). Unexpectedly, onset of HTLV-associated leukemia thus occurs in the absence of increased CD4 þ T-cell proliferation. This dynamics significantly differs from the generalized activation of the T-cell turnover induced by other primate lymphotropic viruses like HIV and SIV.

show abstract

Expression and immunogenicity in rats of recombinant adenovirus 5 DNA plasmids and vaccinia virus containing the HTLV-I-env gene

Cited by 26 publications

References 16 publications

Immunogenicity and Protective Efficacy of Recombinant Human T-Cell Leukemia/Lymphoma Virus Type 1 NYVAC and Naked DNA Vaccine Candidates in Squirrel Monkeys (Saimiri sciureus)

Immunogenicity and Protective Efficacy of Recombinant Human T-Cell Leukemia/Lymphoma Virus Type 1 NYVAC and Naked DNA Vaccine Candidates in Squirrel Monkeys (Saimiri sciureus)

Advances in HTLV-1 Peptide Vaccines and Therapeutics

Reduced cell turnover in lymphocytic monkeys infected by human T-lymphotropic virus type 1

Contact Info

Product

Resources

About